Tilray medicinal pot product proves useful for combating nausea
Tilray Inc, a Canadian cannabis company, is a global leader in cannabis research, production, cultivation, and distribution. A team of Australian researchers recently published preliminary results after finding that one of the Tilray's GMP-produced products shows positive results for diminishing vomiting and nausea for cancer patients undergoing chemotherapy in the world’s first clinical trial.
Published results for the study indicated a significant improvement in the symptoms caused by chemotherapy. Vomiting and nausea for a quarter of the patients taking medicinal cannabis virtually disappeared, and these results were in comparison to the 14 percent of patients who were given a placebo. The pilot phase of the trial included 81 participants and ran for two and a half years.
Who was included in the study
To gain entry into the study, patients were required to have experienced nausea and vomiting while taking chemotherapy despite taking prescribed medication for nausea prevention. Philippe Lucas, Vice President of Global Patient Research and Access at the company, says that controlling nausea and vomiting can help to improve the quality of life for those cancer patients experiencing these symptoms.
The VP of Tilray further believes that managing chemotherapy's side effects through cannabis can save lives by enabling the cancer patient to continue receiving the chemotherapy treatment without the intense bouts of vomiting and nausea. According to researchers, the side effects of medicinal cannabis, such as dizziness, drowsiness, and sedation, outweigh the adverse vomiting and nausea associated with cancer treatment. Medicinal cannabis has proven to offer an improvement to the quality of life for these patients.
Professor Grimison, a medical oncologist, says the trial will now continue with a more extensive phase to determine how well medicinal cannabis helps to reduce chemotherapy's negative side-effects and whether or not it should be considered as a routine treatment for cancer patients. The next part of the trial will see an extra 170 people recruited to take part.
Tilray is supplying the product for the world’s largest medicinal cannabis trial. The Cannabis CINV study is provided by a collaboration that includes the University of Sydney, Chris O'Brien Lifehouse, the NHMRC Clinical Trial Centre and leading New South ales cancer centers. The funding for the trial was provided by the New South Wales government.
Tilray is a pioneer in distributing cannabinoids and cannabis, which is currently serving consumers in 15 countries that span five continents and tens of thousands of patients.
Founded in 2015, CEO Brendan Kennedy and the company made history in 2018 when it became the first Canadian cannabis company to legally export medicinal cannabis to the US for clinical trials. Today Tilray is now exporting its medicinal brands to 13 countries, and the company hopes that those numbers will be doubled in the next two years.
The acquisition of Manitoba Harvest, a hemp food company that supplies about 70 percent of the US hemp food gives Tilray immediate access to 13,500 retail outlets across the United States. Some of these outlets include Costco and Walmart. The launching of the hemp-derived CBD range will be distributed through the Manitoba network, and the future is looking bright for this green company.